Hyperoxia
This condition can occur during oxygen therapy or in certain medical conditions.
Hyperoxia has been studied for its potential therapeutic applications, particularly in the context of conditions such as stroke, traumatic brain injury, and other ischemic disorders.
However, optimizing hyperoxia protocols can be challenging, as the effects can vary depending on factors like duration, oxygen concentration, and method of delivery.
PubCompare.ai helps users locate protocols from literate, pre-prints, and patents while using AI-driven comparisons to identify the best protocols and products for reproducible, evidence-based hyperoxia research.
Most cited protocols related to «Hyperoxia»
To determine the necessary window of oxygen exposure over the first 14 days of life, newborn mouse pups were exposed to 85% O2 for discrete ‘windows’, which included: (1) the first 24 h of life (P1), (2) the first three days of life, starting at P1, up to and including P3; (3) starting at the beginning of P4 and continuing to (and including) P7; (4) the first seven days of life, starting at P1, and continuing to (and including) P7; and (5) the entire first 14 days of life, ending with (and including) P14. All experiments were terminated at P14.
For all oxygen-exposure protocols, nursing dams were rotated every 24 h, to ensure at least one 24 h period of 21% O2 every 2 days. This addresses the oxygen toxicity issues in adult mice, which are highly susceptible to prolonged periods of hyperoxia. Nursing dams received food ad libitum. Mice were maintained in a 12 h:12 h dark/light cycle. All pups were euthanised at the end of P14 with an overdose of pentobarbital (500 mg/kg, intraperitoneal; Euthoadorm, CP-Pharma, Burgdorf, Germany), followed by thoracotomy, then by lung extraction and processing for design-based stereology (Madurga et al., 2014 (link); Mižíková et al., 2015 (link)).
Most recents protocols related to «Hyperoxia»
Example 7
The following Example is an exemplary assay to evaluate VGX-300 and VGX-301-ΔN2 for their ability to inhibit the onset of retinal neovascularization using the ROP model. In this model, postnatal day 7 (P7) mice are exposed to hyperoxia (75% oxygen) for 5 days (to P12). After hyperoxic exposure, P12 mice are returned to normoxia, and administered an intravitreal injection of human isotype control antibody, VGX-300, VGX-301-ΔN2, Eylea (VEGF-Trap), VGX-300+Eylea or VGX-301-ΔN2+Eylea. All mice are then housed under normoxic conditions for 5 days before sacrifice at P17, enucleation and fixation in 10% formalin/PBS. Vessels will be quantified in each group using H&E and/or IHC staining methods.
Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
RNA isolation, reverse transcription, and real-time PCR analysis for the brain, heart, and lung samples extracted at 2 h after CA were performed according to manufacturer instructions. Briefly, total RNAs were extracted and reverse transcribed using TRIzol Reagent® (Invitrogen, Carlsbad, CA) and SuperScript™ IV VILO™ Master Mix with ezDNase™ Enzyme (Invitrogen, Carlsbad, CA), respectively. Real-time PCR was performed using TaqMan™ Fast Advanced Master Mix (Applied Biosystems™, Waltham, MA) on the LightCycler 480 system (Roche Diagnostics, Mannheim, Germany). All primers were purchased from Thermofisher: Glyceraldehyde-3-phosphate dehydrogenase (Gapdh, TaqMan Assay ID: Rn01775763_g1), Interleukin-1 beta (Il1b, Rn00580432_m1), Interleukin-6 (Il6, Rn01410330_m1), Transforming growth factor-beta 1 (Tgfb1, Rn00572010_m1), Intercellular adhesion molecule-1 (Icam1, Rn00564227_m1), Nuclear factor-kappa beta 1 (Nfkb1, Rn01399583_m1), Tumor necrosis factor (Tnf) receptor-associated factor-6 (Traf6, Rn01512911_m1), Caspase-3 (Casp3, Rn00563902_m1), Caspase-9 (Casp9, Rn00581212_m1), Epidermal growth factor (Egf, Rn00563336_m1), and B-cell leukemia/lymphoma-2 (Bcl2) associated X protein (Bax, Rn02532082_g1).
Top products related to «Hyperoxia»
More about "Hyperoxia"
This condition can occur during supplemental oxygen therapy or in certain medical conditions.
Hyperoxia has been extensively studied for its potential therapeutic applications, particularly in the context of conditions such as stroke, traumatic brain injury, and other ischemic disorders.
Optimizing hyperoxia protocols can be challenging, as the effects can vary depending on factors like duration, oxygen concentration, and method of delivery.
PubCompare.ai helps users locate protocols from literarature, pre-prints, and patents while using AI-driven comparisons to identify the best protocols and products for reproducible, evidence-based hyperoxia research.
Researchers often utilize animal models like C57BL/6J mice to study the effects of hyperoxia.
Exposing these mice to hyperoxic conditions in a Plexiglas chamber can provide insights into the underlying mechanisms and potential therapeutic interventions.
Monitoring parameters like reactive oxygen species (ROS) levels using assays like the ROS-Glo™ H2O2 Assay can help evaluate the impact of hyperoxia on cellular processes.
In addition to animal studies, in vitro experiments using cell lines and tissues can also contribute to our understanding of hyperoxia.
Culturing cells under hyperoxic conditions, while monitoring cell viability and proliferation, can shed light on the direct effects of oxygen toxicity.
Incorporating antibiotics like Penicillin and Streptomycin can help maintain sterile cell culture conditions during these experiments.
Ultimately, the insights gained from hyperoxia research, facilitated by tools like PubCompare.ai, can lead to the development of optimized protocols and therapeutic strategies for various ischemic and oxidative stress-related disorders.
By leveraging AI-driven protocol comparisons and a range of experimental models, researchers can advance our understanding of hyperoxia and its clinical implications.